DSS(US:DSS)2026-03-31 20:30Financial Performance - DSS, Inc. reported year-over-year revenue growth and increased printed product sales within the Product Packaging segment for Q1 2025[19]. - Total revenue for the year ended December 31, 2025, increased by 9% to approximately $20.8 million compared to $19.1 million in 2024[134]. - Revenue from printed products rose by approximately 12% to $18.1 million, driven by new and existing customer orders[134]. - Commercial lending revenue fell by approximately 80% to $45,000, attributed to loans going on non-accrual[134]. - Total costs and expenses decreased by 43% to $35.2 million from $61.7 million in 2024[135]. - Interest income decreased by 92% year-over-year to $19,000 in 2025, primarily due to several notes being put on non-accrual as borrowers showed inability to pay timely[145]. - The loss on investments was $807,000 in 2025, a significant decline compared to a gain of $224,000 in 2024, primarily due to the performance of True Partners Capital Holdings Limited[150]. - Net cash used by operating activities was approximately $9.1 million in 2025, compared to $8.8 million in 2024, reflecting a decrease in net loss adjustments[157]. - Net cash provided by investing activities increased to approximately $18.1 million in 2025 from $12.1 million in 2024, including $15.7 million from real estate sales[158]. - Net cash used by financing activities was approximately $14.1 million in 2025, primarily due to payments toward long-term debt[159]. Strategic Initiatives - DSS aims to reduce costs by 15-20% in the upcoming fiscal year to improve profitability and strengthen its financial position[23]. - The Company is strategically expanding key business units, such as Premier Packaging, to drive growth and contribute to long-term revenue generation[22]. - DSS is committed to exploring untapped markets to create scalable and recurring revenue streams across multiple sectors[23]. - The Company is focusing on advancing research and development in emerging sectors, such as biomedical technologies and sustainable packaging[23]. - The Company is implementing metrics-driven accountability systems across all business units to ensure consistent execution of high-priority opportunities[23]. Intellectual Property and Innovation - Impact BioMedical announced the issuance of a U.S. patent related to its 3F™ intellectual property portfolio, expanding its patent protection[21]. - DSS holds nine issued patents and over forty pending patents worldwide, with expiration dates ranging from 2029 to 2040, enhancing its competitive position[48]. - Key products in development include LineBacker for various diseases, Equivir for antiviral treatments, and Laetose, a sugar alternative believed to lower glycemic index by 30%[46]. - The company plans to develop additional new inventions and intellectual property, which will require significant capital and time, with risks of not yielding viable results[88]. - Patent application delays could hinder revenue recognition from internally generated patents and may result in missed licensing opportunities[91]. Market and Customer Concentration - As of December 31, 2025, one customer accounted for approximately 29% of consolidated revenue, indicating a significant reliance on key clients[58]. - The company reported that five customers accounted for 19%, 18%, 13%, 12%, and 11% of its trade accounts receivable balance as of December 31, 2025, highlighting customer concentration risk[73]. - The company emphasizes sustainability in its packaging operations, working closely with suppliers to meet rigorous sustainability standards[60]. Financial Health and Risks - The company has outstanding indebtedness totaling approximately $37.0 million under the LifeCare Agreement, which is currently in default[72]. - The company faces risks related to intellectual property infringement, which could result in costly litigation and negatively affect financial condition[74]. - Future business expansion may strain management and financial resources, requiring additional controls and personnel[83]. - The company is subject to unique risks in its investments in Asia, including regulatory changes and trade restrictions, which could adversely affect earnings[82]. - The company has identified weaknesses in its internal control over financial reporting, which may lead to errors in financial statements and potential restatements, impacting investor confidence and stock price[86]. - The company incurred significant marketing and development costs for bio-health related products, with no assurance of commercial acceptance impacting financial results[76]. Operational Overview - The Company completed the sale of its Plano, Texas facility for $9.5 million, using a portion of the proceeds to reduce outstanding debt[19]. - The Company received FINRA approval for Sentinel Brokers Company to act as an underwriter for corporate securities offerings, including IPOs[18]. - The Company reported four operating segments for 2025, focusing on innovation and diversification, with Premier Packaging and Commercial Lending adapting to market demands[42]. - The Securities and Investment Management segment is a key growth pillar, expanding into real estate investment, digital securities, and wealth management solutions[42]. - Premier Packaging provides custom packaging services across various industries, including pharmaceuticals and consumer goods, and is involved in security printing and brand protection technologies[42]. - American Pacific Financial, the commercial lending arm, focuses on providing commercial loans and acquiring equity positions in undervalued financial entities across the U.S. and Asia[43]. - The Biotechnology segment is dedicated to addressing urgent medical needs, with ongoing research in drug discovery for neurological, oncology, and immuno-related diseases[44]. Compliance and Governance - The Company has been audited by Grassi & Co., CPAs, P.C. from 2022 to 2025, ensuring compliance with PCAOB standards[210]. - The Company’s financial statements for the year ended December 31, 2024, present fairly its financial position in conformity with GAAP[199]. - The valuation of real estate properties is a critical audit matter due to the complexity of valuation models and sensitivity to key assumptions[205]. - The Company is subject to numerous laws and regulations, and changes in these could significantly increase compliance costs[92]. Employee Relations - DSS has 102 employees as of December 31, 2025, and maintains good relations with its workforce, which is not covered by collective bargaining agreements[66].